Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations

Abstract

The findings observed an evidential and significant susceptibility to ICIs combined therapy in patients with <i>BRAF</i>-mutant NSCLC, especially in first-line treatment.